TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01099475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pringle manoeuvre 15 minutes
Description: During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 2-times 15 minutes with 5 minutes reperfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pringle manoeuvre 30 minutes
Description: During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 30 minutes with 5 minutes reperfusion
Study: NCT02627053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Study: NCT03772587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 administered as IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as intravenous (IV) infusion
Study: NCT03311464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Study drug will be administered subcutaneously.
Study: NCT01472458

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality improvement
Description: The primary intervention in this project will be a multi-faceted quality improvement plan targeting improved predictions of neurological outcome and survival after cardiac arrest.
Study: NCT03464851

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid Stenotic Scan (CSS)
Description: Placement of the CSS instrument on the carotid arteries to measure degree of stenosis~of the carotid artery. The CSS scan takes about 1-2 minutes to gather data for real-time analysis by the processor on the device cart.
Study: NCT02499107

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Baked french fries treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fried french fries treatment
Study: NCT02539992

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon® CR/Kinematic Alignment
Description: Total knee replacement using patient-specific cutting guides

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon® CR/Neutral Overall Limb Alignment
Description: Total knee replacement using patient-specific cutting guides

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon® CR/Conventional Limb Alignment
Description: Total knee replacement using traditional instrumentation
Study: NCT02757729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.1%
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.3%
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream vehicle
Description: Topical application
Study: NCT00346957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave acetate 30 mg
Description: 0.5ml administered onto the sclera once every six months for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate 15 mg
Description: 0.5ml administered onto the sclera once every six months for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate 3 mg
Description: 0.5ml administered onto the sclera once every six months for 24 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: 0.5ml administered onto the sclera once every six months for 24 months
Study: NCT01309386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Description: Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine SR
Description: Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
Study: NCT03139734

Intervention type: DEVICE
Group type: OTHER
Intervention: Sacral Neuromodulation
Description: S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
Study: NCT03464851

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid Stenotic Scan (CSS)
Description: Placement of the CSS instrument on the carotid arteries to measure degree of stenosis~of the carotid artery. The CSS scan takes about 1-2 minutes to gather data for real-time analysis by the processor on the device cart.

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid Stenotic Scan (CSS)
Description: Placement of the CSS instrument on the carotid arteries to measure degree of stenosis~of the carotid artery. The CSS scan takes about 1-2 minutes to gather data for real-time analysis by the processor on the device cart.
Study: NCT01949389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy for Insomnia
Description: This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
Study: NCT00596700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Given® Diagnostic System including PillCamTM SB Capsules
Description: Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.~An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa
Study: NCT00830505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol
Description: 2 puffs twice a day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: 2 puffs twice a day for 2 weeks
Study: NCT02918305

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PRDS-001 Renal Denervation Ultrasound System

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Study: NCT03765008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water intake manipulation
Description: for 5 days prior to each experiment subjects will undergo manipulation of their water intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water intake manipulation
Description: for 5 days prior to each experiment subjects will undergo manipulation of their water intake.
Study: NCT00704405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (Peg-IFN)
Description: Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (Peg-IFN)
Description: Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon (Peg-IFN)
Description: Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (Peg-IFN)
Description: Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (Peg-IFN)
Description: Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing \>75 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing \>75 kg.
Study: NCT01240096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine 15 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine 15 mg daily
Study: NCT04596969

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Soluble Fiber Dextrin
Description: Ingredient based on resistant starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble Fiber Dextrin
Description: Ingredient based on resistant starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble Fiber Dextrin
Description: Ingredient based on resistant starch
Study: NCT00704405

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing \>75 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing \>75 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing \>75 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PBO)
Description: Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PBO)
Description: Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
Study: NCT04225689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD-TREAT diet
Description: Dietary intervention
Study: NCT05564260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kaleidescope
Description: watching kaleidescope

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: wearing virtual reality glasses
Study: NCT01500811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell injection
Description: Intra articular injection of chondrocyte
Study: NCT03638167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR806-specific chimeric antigen receptor (CAR) T cell
Description: Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR806-specific chimeric antigen receptor (CAR) T cell
Description: Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
Study: NCT04520503

Intervention type: DRUG
Intervention: Propofol
Description: The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.

Intervention type: DEVICE
Intervention: EEG monitoring
Description: The processed EEG spectrogram and indices, such as patient status index, 95% spectral edge frequency, and suppression ratio, will be obtained from Sedline monitoring device. The raw pre-induction EEG will be extracted from Sedline at the end of induction and it will be analyzed by an external software to calculate the mean frequency, frequency band power and its distribution.
Study: NCT03499145

Intervention type: DEVICE
Intervention: Ophthalmology diagnostic system.
Description: An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
Study: NCT01044225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilengitide EMD 121974
Description: A dose of 2000 mg by IV administration 2 weekly.
Study: NCT01844960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Gastric Band Insertion
Description: Insertion of gastric band though single abdominal incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Incision Gastric Band Insertion
Description: Insertion of gastric band though multiple abdominal incisions
Study: NCT04625179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin and hyaluronic acid and sinus membrane elevation
Description: 3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus membrane elevation without any materials
Description: No materials will be placed at the sinus space.
Study: NCT04596969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble Fiber Dextrin
Description: Ingredient based on resistant starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble Fiber Dextrin
Description: Ingredient based on resistant starch
Study: NCT00890448

Intervention type: OTHER
Intervention: Pharmacogenomic whole blood sampling
Description: 10 mL, whole blood, one sample on Visit 2
Study: NCT03020485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Description: Isomaltulose is a disaccharide made up of one molecule glucose and fructose with a (α1-6) linkage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose is normal table sugar
Study: NCT00475137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
Study: NCT03007303

Intervention type: DRUG
Intervention: Atypical Antipsychotic
Description: Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.

Intervention type: OTHER
Intervention: atypical antipsychotic combined with MECT
Description: The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
Study: NCT02479555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone sodium phosphate injection, USP, 4 mg/mL
Description: Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.~Investigational Drug will be administered via Bullfrog Micro-Infusion Device.
Study: NCT00455169

Intervention type: BIOLOGICAL
Intervention: Trivalent Inactivated Influenza Vaccine
Description: Influenza vaccine

Intervention type: BIOLOGICAL
Intervention: Trivalent Inactivated Influenza Vaccine
Description: Influenza vaccine
Study: NCT01611623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Tablets dose every other day; dose escalation based on safety
Study: NCT04530045

Intervention type: OTHER
Intervention: dosage of concentration of piperacillin and cefepim
Description: Dosage of total plasma concentration of piperacillin and cefepim at different timepoints
Study: NCT03065491

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Combined nutraceutical
Description: Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration: 1 tablet per day
Study: NCT03472638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsomedial prefrontal rTMS
Description: Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsomedial prefrontal rTMS
Description: Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.
Study: NCT03534661

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teduglutide + Normal Saline
Description: Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teduglutide + L-NMMA
Description: Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + L-NMMA
Description: Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
Study: NCT02147613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise training
Description: 3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
Study: NCT01129401

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stonewall Project
Description: The Stonewall Project is an outpatient substance abuse treatment program for methamphetamine-using MSM that includes individual counseling, group counseling, and visits with a psychiatrists where indicated.
Study: NCT01951144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 or Placebo
Description: PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 or Placebo
Description: PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 or Placebo
Description: PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 or Placebo or Lorazepam
Description: Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
Study: NCT02976519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 443651
Description: twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily
Study: NCT03069872

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: Access to fast transvaginal ultrasound through general practice Develop and conduct training for general practicioners in the latest knowledge of ovarian cancer symptomatology
Study: NCT03006536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Li-ESWT
Description: Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Li-ESWT
Description: Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
Study: NCT04288947

Intervention type: OTHER
Group type: OTHER
Intervention: Disrespect and Abuse in Maternity Care
Description: Changing the culture of disrespect and abuse in maternity care